Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States

被引：0
|
作者：
Weiting Liao
Wanting Lei
Mingyang Feng
Yang Yang
Qiuji Wu
Kexun Zhou
Liangliang Bai
Feng Wen
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Cost-effectiveness; Anti-angiogenesis; Immunotherapy; Cabozantinib; Nivolumab; Renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5662 / 5670
页数：8
相关论文
共 50 条
  • [31] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] COST-EFFECTIVENESS OF PEMBROLIZUMAB plus AXITINIB VERSUS NIVOLUMAB plus IPILIMUMAB AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL
    Garmatter, L. P. Leonart
    Berlinski, F.
    Rego, M. A. D. C.
    Bastos, D. A.
    Soares, A.
    Kater, F. R.
    Nunes, A. A.
    Santos, M.
    Riveros, B. Salgado
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S149 - S150
  • [34] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [35] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    [J]. IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [36] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    [J]. FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [37] Economic implications of the first-line treatment of advanced renal cell carcinoma in Thailand: A cost-effectiveness analysis
    Topibulpong, N.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Vinayanuwattikun, C.
    Sriuranpong, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] ECONOMIC IMPLICATIONS OF THE FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THAILAND: A COST-EFFECTIVENESS ANALYSIS
    Topibulpong, N.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Vinayanuwattikun, C.
    Sriuranpong, V
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A513 - A513
  • [39] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
    Berling, M.
    Chaudhary, M. A.
    Yuan, Y.
    Varol, N.
    Dale, P.
    Testa, E.
    Klint, J.
    Lee, A.
    Lubinga, S. J.
    Penrod, J. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S16
  • [40] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
12345